| Literature DB >> 21854577 |
Yohan Robinson1, Christoph E Heyde, Peter Försth, Claes Olerud.
Abstract
Osteoporotic vertebral compression fractures are a menace to the elderly generation causing diminished quality of life due to pain and deformity. At first, conservative treatment still is the method of choice. In case of resulting deformity, sintering and persistent pain vertebral cement augmentation techniques today are widely used. Open correction of resulting deformity by different types of osteotomies addresses sagittal balance, but has comparably high morbidity. Besides conventional vertebral cement augmentation techniques balloon kyphoplasty has become a popular tool to address painful thoracic and lumbar compression fractures. It showed improved pain reduction and lower complication rates compared to standard vertebroplasty. Interestingly the results of two placebo-controlled vertebroplasty studies question the value of cement augmentation, if compared to a sham operation. Even though there exists now favourable data for kyphoplasty from one randomised controlled trial, the absence of a sham group leaves the placebo effect unaddressed. Technically kyphoplasty can be performed with a transpedicular or extrapedicular access. Polymethyl methacrylate (PMMA)-cement should be favoured, since calcium phosphate cement showed inferior biomechanical properties and less effect on pain reduction especially in less stable burst fractures. Common complications of kyphoplasty are cement leakage and adjacent segment fractures. Rare complications are toxic PMMA-monomer reactions, cement embolisation, and infection.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21854577 PMCID: PMC3170323 DOI: 10.1186/1749-799X-6-43
Source DB: PubMed Journal: J Orthop Surg Res ISSN: 1749-799X Impact factor: 2.359
Guidelines for indications and contraindications for kyphoplasty
| - | |
| - | |
| | |
| - Flexion-/distraction and rotational injuries (AO type B and C) | |
| - Medical contraindications (bleeding disorders, sepsis, etc) | |
| - PMMA-allergy |
Figure 1Transpedicular approach for balloon kyphoplasty. After entry in the craniolateral pedicle (red cross) in the p-a-projection (a), the medial cortex of the pedicle is first breached when the vertebral body is entered in the lateral projection (blue cross) (b). After preparation of the working channel a balloon can be placed in the vertebral body.
Figure 2Unilateral extrapedicular costotransversary approach for balloon kyphoplasty. Following the cranioposterior part of the respective rib into the costotransversary space (c) allows extrapedicular access to the vertebral body in the thoracic spine. Due to the far lateral approach a single balloon is placed in the middle of the vertebral body (a, b).
Overview on comparative clinical trials of kyphoplasty
| Author | Year | Design | Level of evidence | Control Group | Control n (levels) | Kyphoplasty n (levels) | Follow-up | Outcome |
|---|---|---|---|---|---|---|---|---|
| Weisskopf et al. [ | 2003 | Retrospective | IIIb | non-surgical | 20 (35) | 22 (37) | 10 days | Improvement in VAS (p < 0.001) Reduced days in hospital (p < 0.01) |
| Fourney et al. [ | 2003 | Retrrospective | IIIb | vertebroplasty | 34 (65) | 15 (32) | 4,5 months | No significant differences in VAS and ODI Improvement of kyphosis with kyphoplasty (p < 0.01) |
| Komp et al. [ | 2004 | Prospective | IIb | non-surgical | 19(19) | 21(21) | 6 months | Improvement of VAS and ODI with kyophoplasty (p < 0.01) |
| Kasperk et al [ | 2005 | Prospective | IIb | non-surgical | 20 (33) | 40 (72) | 12 months | Improvement of VAS (p < 0.01) and improvement of kyphosis (p < 0.001) with kyphoplasty |
| Grohs et al. [ | 2005 | Prospective | IIb | vertebroplasty | 23 (29) | 28 (35) | 24 months | No significant difference in ODI, but improvement of VAS with kyphoplasty (p < 0.05). No significant improvement of kyphosis |
| Masala et al. [ | 2005 | Retrospective | IIIb | vertebroplasty | 26 (33) | 7 (7) | 6 months | No significant difference in VAS. |
| Pflugmacher et al [ | 2005 | Prospective | IIb | vertebroplasty | 20 (32) | 22 (35) | 12 months | No significant difference in VAS and ODI. Improvement of kyphosis with kyphoplasty (p < 0.05) |
| De Negri et al. [ | 2007 | Prospective | IIb | vertebroplasty | 10 (18) | 11 (15) | 6 months | No significant difference in VAS and ODI. |
| Zhou et al. [ | 2008 | Prospective | IIIb | vertebroplasty | 42 | 56 | 12 months | No significant differences in VAS, operation time and blood loss. Improved vertebral height restoration with kyphoplasty (p < 0.01). |
| Wardlaw et al. [ | 2009 | Randomised | Ib | non-surgical | 149 | 151 | 12 months | Significant improvement in EQ-5D (p < 0.05), RMDQ (p < 0.001) VAS (p < 0.0001). |
| Schmelzer-Schmied et al. [ | 2009 | Prospective | IIb | non-surgical | 20 | 20 | 12 months | Significant greater improvement of VAS (p < 0.05) with kyphoplasty, which was lost after 3 months, and vertebral height preservation after 12 months (p < 0.01) |
| Schofer et al. [ | 2009 | Prospective | IIIb | vertebroplasty | 30 | 30 | 13 months | No significant differences in VAS and SF-36. Greater improvement of kyphotic angle with kyphoplasty (p < 0.001) |
| Li X et al [ | 2011 | Prospective | IIIb | vertebroplasty | 40 | 45 | 12 months | No significant differences in VAS and ODI. Significantly greater improvement of kyphotic angle with kyphoplasty (p < 0.01) |
VAS: Visual Analogous Scale, ODI: Oswestry Disability Index, EQ-5D: EuroQoL, RMDQ: Roland Morris Disability Questionnaire, SF-36: Short Form Health Survey.